Cosmo valuation report: GI Genius, Winlevi, and Breezula to drive future growth

Tuesday, May 13, 2025 @ 12:00 am

Cosmo is one of the few SIX-listed biopharma companies with cash resources to fund clinical development and pay dividends due to a strong balance sheet and sustainable revenues from eight marketed products. Growth products GI Genius, Winlevi, Breezula are expected to drive significant growth and margin expansion.

Key catalysts include:

1. Investor Day (1 July 2025)
2. Winlevi CHMP re-examination response (Q3 2025)
3. Breezula 6-month topline results phase III AGA trial (early H2 2025)

Cosmo Valuation Report

You may also be interested in

Beware of fraudulent emails impersonating the Swiss Biotech Association

Don’t fall for fraudsters! Cyber criminals can reach you easily with today's communication means. We regularly detect fraudulent emails attempting to steal your passwords — both personal and for our systems — through phishing attacks. Smishing (SMS, text messages) or vishing (phone calls) are also a common way to retrieve information from you. With seemingly legitimate messages the criminals
October 8, 2024

Beech Biotech: USD 1.9 million to advance therapeutic approach for preeclampsia

Disease-Modifying Potential of Beech Biotech’s “Mother-Only” Antibody Programme and Platform Technology Further Underscored by Gates Foundation Grant
June 27, 2025

Sophia Genetics launches podcast series to demystify AI in healthcare

SOPHiA GENETICS has launched a new podcast series titled Decoded, hosted by CEO Dr. Jurgi Camblong. The series aims to make complex medical technologies, from AI-powered diagnostics to liquid biopsy, accessible and understandable to healthcare professionals and the wider public.
June 24, 2025

InSphero and Brenus Pharma: 3D tumor spheroids mimicking in vivo human colorectal cancer conditions

Brenus Pharma, a French biotech developing next-generation first-in-class immunotherapies, and InSphero, a Swiss leader in 3D cell-based assay technologies, presented promising data at the European Association for Cancer Research 2025 annual congress. These data confirm the use of 3D tumor spheroids for potency testing of STC-1010, Brenus’ lead candidate for colorectal cancer.
June 19, 2025

Pharvaris highlights their drugs potential to prevent and treat bradykinin-mediated angioedema attacks

Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced a summary of data that were presented at the European Academy of Allergy and Cl
June 16, 2025

HGF recognized for 7th year in a row by Financial Times

HGF has once again been ranked ‘Gold’ across all six bands in the Financial Times Special Report – Europe’s Leading Patent Law Firms 2025.
June 12, 2025